Corient Capital Partners, LLC Humanigen, Inc Transaction History

Corient Capital Partners, LLC

  • $1.34 Billion
  • Q3 2022

A detailed history of Corient Capital Partners, LLC transactions in Humanigen, Inc stock. As of the latest transaction made, Corient Capital Partners, LLC holds 10,461 shares of HGEN stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,461
Previous 10,461 -0.0%
Holding current value
$0
Previous $19,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022
BUY
$1.76 - $3.33 $18,411 - $34,835
10,461 New
10,461 $19,000

Others Institutions Holding HGEN

# of Institutions
4
Shares Held
558K
Call Options Held
0
Put Options Held
0
View Full List

About HUMANIGEN, INC

HGEN Quotes by TradingView
  • Ticker HGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,661,000
  • Description
  • Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...
More about HGEN
Track This Portfolio

Track Corient Capital Partners, LLC Portfolio

Follow Corient Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Corient Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Corient Capital Partners, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email